OBJECTIVES: To assess the incidence and degree of MRI contrast enhancement in liver tumours following successful percutaneous cryoablation. METHODS: Thirty-eight patients with liver metastases (n = 29) or hepatocellular carcinoma (n = 9) underwent percutaneous cryoablation of 45 tumours between March 2004 and June 2009, with complete ablation zone coverage of the tumour and no local recurrence on follow-up imaging to date (range 3-60 months, mean 16). Contrast-enhanced MRI was used to assess 45 tumours at 24 h, 32 tumours at 2-4 months, and 21 tumours at 5-7 months. Percentage of tumours with contrast enhancement was assessed using dynamic spoiled gradient echo T1-weighted images. RESULTS: Twenty-four hours post-cryoablation, 23 out of 45 tumours (51%) enhanced compared with 42 out of 43 (98%) pre-ablation (p < 0.001). Mean percentage tumour enhancement decreased from 157% (range 26-745%) pre-ablation, to 107% (27-260%) at 24 h (p = 0.003), and 43% (24-103%) at 2-4 months (p < 0.001). The incidence and degree of tumour enhancement decreased through 5-7 months. CONCLUSIONS: Unlike previously reported studies of radiofrequency ablation, successful cryoablation of liver tumours is often associated with persistent tumour contrast enhancement on MRI performed at 24 h and decreasing over 2-7 months. KEY POINTS: • Liver neoplasms often demonstrate MRI contrast enhancement following successful percutaneous cryoablation. • This differs from radiofrequency ablation techniques where contrast enhancement suggests residual tumour • This difference could potentially lead to important errors in follow up strategies.
OBJECTIVES: To assess the incidence and degree of MRI contrast enhancement in liver tumours following successful percutaneous cryoablation. METHODS: Thirty-eight patients with liver metastases (n = 29) or hepatocellular carcinoma (n = 9) underwent percutaneous cryoablation of 45 tumours between March 2004 and June 2009, with complete ablation zone coverage of the tumour and no local recurrence on follow-up imaging to date (range 3-60 months, mean 16). Contrast-enhanced MRI was used to assess 45 tumours at 24 h, 32 tumours at 2-4 months, and 21 tumours at 5-7 months. Percentage of tumours with contrast enhancement was assessed using dynamic spoiled gradient echo T1-weighted images. RESULTS: Twenty-four hours post-cryoablation, 23 out of 45 tumours (51%) enhanced compared with 42 out of 43 (98%) pre-ablation (p < 0.001). Mean percentage tumour enhancement decreased from 157% (range 26-745%) pre-ablation, to 107% (27-260%) at 24 h (p = 0.003), and 43% (24-103%) at 2-4 months (p < 0.001). The incidence and degree of tumour enhancement decreased through 5-7 months. CONCLUSIONS: Unlike previously reported studies of radiofrequency ablation, successful cryoablation of liver tumours is often associated with persistent tumour contrast enhancement on MRI performed at 24 h and decreasing over 2-7 months. KEY POINTS: • Liver neoplasms often demonstrate MRI contrast enhancement following successful percutaneous cryoablation. • This differs from radiofrequency ablation techniques where contrast enhancement suggests residual tumour • This difference could potentially lead to important errors in follow up strategies.
Authors: S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman Journal: Radiology Date: 2005-04-21 Impact factor: 11.105
Authors: S Rossi; E Buscarini; F Garbagnati; M Di Stasi; P Quaretti; M Rago; A Zangrandi; S Andreola; D Silverman; L Buscarini Journal: AJR Am J Roentgenol Date: 1998-04 Impact factor: 3.959
Authors: Christopher A Porter; David A Woodrum; Matthew R Callstrom; Grant D Schmit; Sanjay Misra; J William Charboneau; Thomas D Atwell Journal: AJR Am J Roentgenol Date: 2010-03 Impact factor: 3.959
Authors: Yang Guang; Yukun Luo; Yan Zhang; Mingbo Zhang; Nan Li; Ying Zhang; Jie Tang Journal: J Cancer Res Clin Oncol Date: 2017-03-24 Impact factor: 4.553
Authors: Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do Journal: Abdom Radiol (NY) Date: 2018-01